Renal cell carcinoma: Management of advanced disease

Journal of Urology

Volumn 161, Issue 2, 1999, Pages 381-387

  Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinoma, renal cell; Disease management; Interleukin 2

Indexed keywords

CANCER STAGING; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; NEPHRECTOMY; PALLIATIVE THERAPY; PATHOLOGY; REVIEW;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEPHRECTOMY; PALLIATIVE CARE;

EID: 0033074437     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61897-4     Document Type: Review

References (42)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1998. Cancer J. Clin., 48: 6, 1998.
2. Stenzel, A. and deKernion, J. B.: Pathology, biology, and clinical staging of renal cell carcinoma. Sem. Oncol. suppl., 16:3, 1989.
3. Linehan, W. M., Shipley, W. and Parkinson, D.: Cancer of the kidney and ureter. In: Cancer: Principles and Practice of Oncology. Edited by V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg. Philadelphia: J. B. Lippincott, pp. 1023-1051, 1993.
4. Miller, B. A., Ries, L. A. G., Hankey, B. F., Kosary, C. L. and Edwards, B. K.: Cancer Statistics Review: 1973-1990. NIH pub. no. 93-2789. Bethesda, Maryland: National Cancer Institute, 1993.
5. Kessler, O., Mukamel, E., Hadar, H., Gillon, G., Konechezky, M. and Servadio, C.: Effect of improved diagnosis of renal cell carcinoma on the course of the disease. J. Surg. Oncol., 57: 201, 1994.
6. Bretheau, D., Lechevallier, E., Eghazarian, C., Grisoni, V. and Conlange, C.: Prognostic significance of incidental renal cell carcinoma. Eur. Urol., 27: 319, 1995.
7. Yu, M. C., Mack, T. M., Hansich, R., Cicioni, C. and Henderson, B. E.: Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for RCC. J. Natl. Cancer Inst., 77: 351, 1986.
8. Franklin, J. R., Figlin, R. and Belldegrun, A.: Renal cell carcinoma: basic biology and clinical behavior. Sem. Urol. Oncol., 14: 208, 1996.
9. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma. New Engl. J. Med., 335: 865, 1996.
10. Cohen, A. J., Li, F. P., Berg, S., Marchetto, D. J., Tsai, S., Jacobs, S. C. and Brown, R. S.: Hereditary renal-cell carcinoma associated with a chromosomal translocation. New Engl. J. Med., 301: 592, 1979.
11. Pathak, S., Strong, L. C., Ferrell, R. E. and Trindale, A.: Familial renal cell carcinoma with a 3:11 chromosome translocation limited to tumor cells. Science, 217: 939, 1982.
12. Linehan, W. M., Lerman, M. I. and Zbar, B.: Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. J.A.M.A., 273: 564, 1995.
13. Seizinger, B. R., Rouleau, G. A., Ozelius, L. J., Lane, A. H., Farmer, G. E., Lamiell, J. M., Haines, J., Yuen, J. W., Collins, D. and Majoor-Krakauer, D.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature, 332: 268, 1988.
14. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassilion, E., Oldfield, E. H., Klausner, R. D. and Linehan, W. M.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA, 93:10589, 1996.
15. Illiopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr. and Goldberg, M. A.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA, 93: 10595, 1996.
16. Mulders, P., Figlin, R., deKernion, J. B., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W. and Belldegrun, A.: Renal cell carcinoma: recent progress and future directions. Cancer Res., 57: 5189, 1997.
17. Glenn, G. M., Linehan, W. M., Hosoe, S., Latif, F., Yao, M., Choyke, P., Gorin, M. B., Chew, E., Oldfield, E. and Manolatos, C.: Screening for von Hippel-Lindau disease by DNA polymorphism analysis. J.A.M.A., 267: 1226, 1992.
18. Yagoda, A., Abi-Rached, B. and Petrylak, D.: Chemotherapy for advanced renal cell carcinoma, 1983-1993. Sem. Oncol., 22: 42, 1995.
19. Warner, E., Tobe, S. and Pei, Y.: Phase I trial of vinblastine (VBL) with oral cyclosporine-A (CSA) as a multidrug resistance modifier in renal cell carcinoma (RCC). Proc. Amer. Soc. Clin. Oncol., 11: 204, 1992.
20. Lemon, S., Meadows, B. and Fojo, A.: A phase I study of infusional vinblastine with the P-glycoprotein antagonist PSC 833 in patients with metastatic cancer. Proc. Amer. Soc. Clin. Oncol., 14: 479, 1995.
21. Dexeus, F. H., Logothetis, C. J., Sella, A., Amato, R., Kilbourn, R., Ogden, S., Striegel, A., Kwan, J. and Newman, R. A.: Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J. Urol., 146: 709, 1991.
22. deKernion, J. B., Sarna, G., Figlin, R., Lindner, A. and Smith, R. B.: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol., 130: 1063, 1983.
23. Quesada, J. R., Swanson, D. A. and Gutterman, J. U.: Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J. Clin. Oncol., 3: 1086, 1985.
24. Wirth, M. P.: Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. N. Amer., 20: 283, 1993.
25. Fisher, R. I., Rosenburg, S. A., Sznol, M., Parkinson, D. R. and Fyfe, G.: High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Amer., 3: S70, 1997.
26. Bukowski, R. M.: Natural history and therapy of metastatic renal cell carcinoma. Cancer, 80: 1198, 1997.
27. Figlin, R., Pierce, W. C., Kaboo, R., Tso, C. L., Moldawer, N., Gitlitz, B., deKernion, J. and Belldegrun, A.: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol., 158: 740, 1997.
28. Figlin, R.: Renal cell carcinoma and interleukin-2: what are the endpoints? Cancer J. Sci. Amer., 3: S67, 1997.
29. Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Perry, J., Mousseau, M., Philip, T. and Tursz, T.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Group Francais dimmunotherapie. New Engl. J. Med., 338: 1272, 1998.
30. Yang, J. C. and Rosenberg, S. A.: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Amer., 3: S79, 1997.
31. Figlin, R., Gitlitz, B., Franklin, J., Dorey, F., Moldawer, N., Rausch, J., deKernion, J. and Belldegrun, A.: Interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Amer., 3: S92, 1997.
32. deKernion, J. B., Ramming, K P. and Smith, R. B.: The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol., 120: 148, 1978.
33. Montie, J. E., Stewart, B. H. and Stratton, R. A.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol., 117: 272, 1977.
34. Franklin, J., Figlin, R., Rauch, J., Gitlitz, B. and Belldegrun, A.: Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Sem. Urol. Oncol., 14: 230, 1996.
35. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K. and Gilboa, E.: Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res., 50: 7820, 1990.
36. Gansbacher, B., Zier, K, Daniels, B., Cronin, K., Bannerji, R. and Gilboa, E.: Interleukin-2 gene transfer into tumor cells abrogates tumorigenecity and induces protective immunity. J. Exp. Med., 172: 1217, 1990.
37. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M. and Pardoll, D. M.: Treatment of established renal cell cancer by tumor cells engineered to secrete interleukin-4. Science, 254: 713, 1991.
38. Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O. and Fleuren, G. J.: Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol., 11: 738, 1993.
39. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H. and Oosterwijk, E.: Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res., 55: 5864S, 1995.
40. Steffens, M. G., Boerman, O., Oosterwijk-Wakka, J. C., Oosterhof, G. O., Witjes, J. A., Koenders, E. B., Oyen, W. J., Buijs, W. C., Debruyne, F. M., Corstens, F. H. and Oosterwijk, E.: Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15: 1529, 1997.
41. Mulders, P., Gitlitz, B. and Tso, C. L.: Biologic characterization of dendritic cells isolated from patients with advanced renal cell carcinoma (RCC) for potential use in adoptive immunotherapy. Proc. Amer. Soc. Clin. Oncol., 16: 442A, 1997.
42. Gitlitz, B. J., Mulders, P. and Tso, C. L.: Specific anti-tumor response against human renal cell carcinoma by dendritic cells loaded with tumor antigens. Proc. Amer. Assn. Cancer Res., 38: 345, 1997.